These results might allow to develop therapies with increased specificity, enhanced target reactivity and long-term anti-tumor reactivity using a broader array of immune effector cells restricted by classical (MHC class I/II) or non-classical (CD1 and MR1) MHC molecules. Here, HLA-C is linked to neoplasm.